Hemophilia without prophylaxis: Assessment of joint range of

COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA, International Journal of Technology Assessment in Health Care

Treatment of hemophilia: a review of current advances and ongoing issues. - Abstract - Europe PMC

PDF] Guidelines for the management of haemophilia in Egypt

Full article: Joint status and related risk factors in patients with severe hemophilia A: a single-center cross-sectional study

Managing Chronic Pain in Patients with Hemophilia

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study - ScienceDirect

The bleeding phenotype in people with nonsevere hemophilia - ScienceDirect

Severe Hem A Patients Showing Bleeds, Physical Limits With Prophylaxis

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults - Research and Practice in Thrombosis

Functional Independence Score in Hemophilia (FISH) - eLearning Platform

PDF) Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Evaluating clinical joint status in boys with haemophilia receiving